Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial

BACKGROUND: A substantial change in trial methodology for solid tumours has taken place, in response to increased understanding of cancer biology. FOCUS4 is a phase 2–3 trial programme testing targeted agents in patients with advanced colorectal cancer in molecularly stratified cohorts. Here, we aim...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Lancet Gastroenterol Hepatol
Prif Awduron: Adams, Richard, Brown, Ewan, Brown, Louise, Butler, Rachel, Falk, Stephen, Fisher, David, Kaplan, Richard, Quirke, Phil, Richman, Susan, Samuel, Leslie, Seligmann, Jenny, Seymour, Matt, Shiu, Kai Keen, Wasan, Harpreet, Wilson, Richard, Maughan, Tim
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Elsevier B.V 2017
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6125825/
https://ncbi.nlm.nih.gov/pubmed/29254887
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2468-1253(17)30394-1
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg